Markus Haeberlein PhD, MSc

Dr. Haeberlein joined Proteostasis Therapeutics in 2012. Previously, Dr. Haeberlein spent 15 years at AstraZeneca in positions of increasing responsibility, most recently as Director, Head of Medicinal Chemistry, CNS and Pain IMed, where he oversaw more than 100 scientists and contributed to over 15 neurology and pain drug candidates as well as novel PET ligands for Alzheimer's disease. Starting in 2009, he was also Chair of AstraZeneca's Global Chemistry Network, overseeing all global chemistry activities at the Company. He received a Ph.D. in Physical Chemistry/Computational Chemistry and a MSc in Physical Chemistry/Biochemistry/Organic Chemistry from KTH Royal Institute of Technology in Stockholm, Sweden. He currently serves on the board of Swedish National Committee of Chemistry and has been the recipient of multiple awards for his studies and teaching.